Showing results (1901-1910 of 9,980) with videos related to

Sort By:
Pageof 998
Leukemia & Lymphoma|January 5, 2024
Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trialsSuheil Albert Atallah-Yunes, Arushi Khurana, Matthew Maurer
Leukemia & Lymphoma|January 2, 2024
Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantationMuhammad Umair Mushtaq, Moazzam Shahzad, Muhammad K Amin, et al.
Leukemia & Lymphoma|January 23, 2024
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignanciesEytan M Stein, Amir T Fathi, Wael A Harb, et al.
Leukemia & Lymphoma|November 7, 2023
Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphomaAustin D Newsam, Caroline A Coughlin, Asaad Trabolsi, et al.
Leukemia & Lymphoma|July 26, 2024
Long-term survival outcome of childhood acute myeloid leukemia: a 43-year experience in Thailand, a resource-limited countryPornpun Sripornsawan, Shevachut Chavananon, Sirinthip Kittivisuit, et al.
Leukemia & Lymphoma|July 1, 2024
Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profilesDeepthi Suresh, Pulkit Rastogi, Amanjit Bal, et al.
Leukemia & Lymphoma|September 5, 2024
The impact of initial tumor bulk in DLBCL treated with DA-EPOCH-R vs. R-CHOP: a secondary analysis of alliance/CALGB 50303Claire M Lanier, Niema B Razavian, Sydney Smith, et al.
Leukemia & Lymphoma|September 3, 2024
Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insightsTinatin Muradashvili, Yuxin Liu, Jennifer VanOudenhove, et al.
Leukemia & Lymphoma|May 24, 2024
Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trialsMonique C Minnema, Xiang Yin, Ruthanna Davi, et al.
Leukemia & Lymphoma|June 10, 2024
Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphomaJulie E Chang, Tuo Wang, KyungMann Kim, et al.
Pageof 998